Chronic Inflammation Plays a Role in Many Diseases

While acute inflammation in response to injury or infection is generally normal and necessary, there is growing evidence that chronic inflammation appears to play a role in many diseases. Although there is less evidence that eating an anti-inflammatory diet plays a role in helping the body respond to chronic inflammation, foods that are part of the Mediterranean diet are generally recommended as part of an otherwise healthy lifestyle.1

C-reactive protein (CRP), a marker of inflammation, is produced by the liver and other organs in response to the release of inflammatory mediators such as interleukin-6 by immune cells following infection and other conditions associated with tissue injury and inflammation. A high level of CRP in the blood merely means that inflammation is present somewhere in the body.2 While doctors don’t agree on the implications of high CRP levels, and some studies have been inconclusive or negative, some believe there’s a correlation between high CRP levels and a number of inflammatory diseases.3 The Physicians’ Health Study found that among healthy adult men, those with a high level of CRP were 3X more likely to have a heart attack than those with low levels of CRP. This was among men who had no previous history of heart disease.4 According to the Cleveland Clinic, the Harvard Women’s Health Study showed that high CRP levels were more predictive of coronary conditions and stroke in women than were high cholesterol levels. High cholesterol is a more commonly cited risk factor.5

Furthermore, a Danish group studied a prospective cohort of 2,910 patients with invasive breast cancer to assess the implications of elevated CRP levels on overall health. They found that women with elevated CRP levels at the time of diagnosis were associated with reduced disease-free and overall survival. In addition, these women had an increased risk of death from breast cancer, independent of established prognostic tumor characteristics and lifestyle factors.6  

The clinical trial that OliVentures conducted in Spain (45 patients) sought to demonstrate that the unique combination of natural ingredients in PureVida™ could lower CRP levels in women who had survived breast cancer. The trial also sought to demonstrate that PureVida™ could reduce joint pain associated with the intake of aromatase inhibitors, a therapy often prescribed in the treatment of hormone-sensitive breast cancer.a,7-9

This product is not intended to diagnose, treat, cure or prevent cancer or any other disease. Because only one trial, with 45 participants, has been performed (and the results of the trial have not yet been peer reviewed), more research is needed to confirm that the results of that trial are valid.a,*

PureVida™ Reduced CRP, A Key Blood Marker of Inflammation, and Pain in OliVenture's Clinical Trial

PureVida™ is a patented combination of 3 very special ingredients that have anti-inflammatory properties:

  • Trephenol™ olive fruit extract (a patented blend of olive polyphenols that includes hydroxytyrosol and tyrosol)
  • Curcumin C3 Complex®, a patented blend of 3 curcuminoids obtained from dried turmeric roots (developed and supplied by Sabinsa Corporation)
  • Marine omega-3s, primarily the essential fatty acids EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) (primarily supplied by AlaskOmega®)

PureVida™ Was Tested in a Prospective Clinical Trial

In a trial conducted by OliVentures, PureVida™ was clinically tested in Spain. In this prospective clinical trial, 45 women (mean age of 59 years) diagnosed with hormone receptor−positive breast cancer who were receiving aromatase inhibitor therapy intended to reduce the odds of cancer recurrence were studied. All women in the study were between 2 and 5 years from their initial surgery for breast cancer, had not received chemotherapy for at least 6 months, and had no evidence of disease. Each patient received treatment with PureVida™ for 30 days and was monitored for 60 days.a,11

Results of the PureVida™ Trial

Study results showed a statistically significant reduction in blood CRP levels, a marker of inflammation, and this effect was maintained over a period of 60 days (p=0.007).a

  • 70% of patients had a decrease in CRP (45 patients with CRP data at analysis point included), and the average percent decrease in CRP was 35% (p=0.007)a
  • CRP reduction at day 60 was statistically significant (p=0.04), which indicated that the effect could be maintained over timea
  • PureVida™ reduced CRP in 70% of the patients studieda
    • In patients whose CRP levels were reduced (2.5X cut-off level), there was a 47% reduction in CRP (a significant reduction at day 30 [p=0.03] and at day 60 [p=0.04])
      • Even in patients with 1.5X basal CRP, there was a significant CRP reduction of 26% (p=0.03)

PureVida™ Reduced Blood CRP Levels, a Marker of Inflammation

PureVida™ Reduced Pain in Patients Taking Aromatase Inhibitors11

Side Effects of PureVida™ During Clinical Study

In the safety analysis of this trial, adverse events included abdominal pain in 1 patient (2.2%), constipation in 5 patients (11.1%), headache in 3 patients (6.7%), and abnormal product taste (fish taste) in 14 patients (31.1%). No patients had to discontinue therapy due to these adverse events.

Our Commitment—Devoted to Better Health, Naturally

OliVentures is committed to the idea that science matters. Because of this, we intend to directly conduct and sponsor scientific studies in order to complement research done over the last few decades by well-respected institutions and to optimize our product ingredients and formulations.

Feel the Benefits of the PureVida Power of 3™

• Supports Heart, Breast, and Joint Health*

• Clinically evaluateda

• Formulation patent-pending

aIn a prospective, multicenter, pilot study of 45 postmenopausal women (mean age 59 years) with Stage 0-IIIA hormone receptor−positive breast cancer receiving stable doses of adjuvant aromatase inhibitor therapy for 2 to 5 years from their diagnosis, PureVida™ significantly reduced C-reactive protein (CRP) levels (p<0.05). In 45 patients examined for safety, reported adverse events (AEs) included abdominal pain in 1 patient (2.2%), constipation in 5 patients (11.1%), headache in 3 patients (6.7%), and abnormal product taste (fish taste) in 14 patients (31.1%). No patients had to discontinue therapy due to AEs. This study was conducted by OliVentures. There has been substantial separate research into the potential benefits of each of the ingredients in PureVida™. The PureVida™ trial has not been peer reviewed and more research is needed before drawing any final conclusions.

*This product is not intended to diagnose, treat, cure, or prevent any disease. Supportive but not conclusive research shows that consumption of EPA and DHA omega-3 fatty acids may reduce the risk of coronary heart disease. Limited clinical evidence indicates that PureVida™ may lower elevated CRP levels. CRP is one of several markers of inflammation in the body. Limited clinical evidence indicates that PureVida™ may reduce joint pain in women taking aromatase inhibitors. These statements have not been evaluated by the U.S. Food and Drug Administration (FDA).

  1. Bauer B. Buzzed on inflammation. Mayo Clinic Health Letter website. Accessed July 8, 2017.
  2. Robbins C. What does a high c-reactive protein level indicate? Livestrong website. Updated April 15, 2015. Accessed July 8, 2017.
  3. C-reactive protein test. Healthline website. Reviewed May 22, 2017. Accessed July 8, 2017.
  4. Ridker PM, Glynn RJ, Hennekens CH. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation. 1998;97(20):2007-2011.
  5. Blood tests to determine risk of coronary artery disease: c-reactive protein. Cleveland Clinic website. Accessed July 8, 2017.
  6. Allin KH, Nordestgaard BG, Flyger H, Bojesen SE. Elevated pre-treatment levels of plasma C-reactive protein are associated with poor prognosis after breast cancer: a cohort study. Breast Cancer Res. 2011;13(3):R55.
  7. Murphy CC, Bartholomew LK, Carpentier MY, Bluethmann SM, Vernon SW. Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review. Breast Cancer Res Treat. 2012;134(2):459-478.
  8. Sestak I, Cuzick J, Sapunar F, et al. Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis. Lancet Oncol. 2008;9(9):866-872.
  9. Crew KD, Greenlee H, Capodice J, et al. Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol. 2007;25(25):3877-3883.
  10. Taber’s Online Medical Dictionary. website. Accessed June 30, 2017.
  11. Data on file. OliVentures, Inc. Raleigh, NC.